RepliCel Poised To Partner Up For Precision-Control Dermal Injector
Executive Summary
RepliCel Life Sciences is set to unveil in July the first functioning prototype of its next-generation dermal injector, which the company said has already sparked the interest of big dermal filler manufacturers. While the technology had been developed originally to deliver RepliCel's cell therapies for pattern baldness and aging or sun-damaged skin, the company believes the injector's unique features – including electronically-controlled dosing and delivery – allow it to be used in myriad applications.